SSCRIPTURAclinical · decision · supportScriptura
Sign in
Patient sign inClinician sign in

Clinician reference, evidence review

Semaglutide

Ozempic, Wegovy, Rybelsus

GLP-1 receptor agonist, FDA approved

Reviewed by: Sabrina Runbeck, PA-C, MHS, MPH, Co-Founder, Scriptura Health. Physician assistant, public health master's, health sciences master's. Sabrina reviews the clinical layer of Scriptura Health, and she reviews every compound reference on this site.

Published: 2026-07-08. This page is an evidence review, not clinical instruction, and does not recommend dosing, cadence, routes, or prescribing decisions. Prescribing is the responsibility of a licensed clinician evaluating a specific patient.

Regulatory posture

Semaglutide is FDA approved and marketed as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management and cardiovascular risk reduction. Because an FDA approved product is commercially available, compounding is tightly restricted and is generally permitted only under narrow conditions such as a documented shortage or specific patient needs. It is not a controlled substance under the DEA.

Mechanism, plain English

Semaglutide imitates GLP-1, a natural gut hormone the body releases after eating. It helps the pancreas release insulin when blood sugar is high, slows how fast the stomach empties, and signals the brain to reduce appetite, so people tend to eat less. These combined effects lower blood sugar and support weight loss.

Evidence landscape

Semaglutide has one of the strongest evidence bases among the peptides in this review, supported by large randomized controlled trials. The STEP program showed substantial and sustained weight loss in adults with overweight or obesity compared with placebo. The SELECT trial demonstrated a reduction in major cardiovascular events in people with obesity and established cardiovascular disease but without diabetes, extending its evidence beyond weight and glucose. A systematic review and meta-analysis confirmed meaningful weight loss with an acceptable safety profile, with gastrointestinal effects such as nausea being the most common adverse events. Reported safety concerns center on gastrointestinal tolerability and require monitoring in practice.

Primary PubMed citations

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity , Wilding JPH et al, New England Journal of Medicine, 2021. PMID: 33567185
  2. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes , Lincoff AM et al, New England Journal of Medicine, 2023. PMID: 37952131
  3. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis , Tan HC et al, Journal of the ASEAN Federation of Endocrine Societies, 2022. PMID: 36578889

Citations selected from the PubMed literature. Every URL was checked at publication time. Scriptura's daily PubMed scan surfaces new studies for each compound as they index. See the regulatory and literature layers on the demo.

Scope of this page

This is a plain English summary of the peer reviewed literature and current regulatory posture. It is not a substitute for a licensed clinician's judgment on a specific patient. It does not recommend dosing, cadence, or route. Where the literature is limited or preclinical, this page says so, so a prescriber can weigh marketing claims against what the trials actually show.

More clinician references

  • BPC-157 , Cytoprotective peptide, research grade, not FDA approved
  • TB-500 , Regenerative peptide, research grade, not FDA approved
  • Tirzepatide , Dual GIP and GLP-1 receptor agonist, FDA approved
  • Retatrutide , Triple GIP, GLP-1, and glucagon receptor agonist, investigational, not FDA approved
  • CJC-1295 , Growth hormone releasing hormone analog, research grade, not FDA approved
  • Ipamorelin , Growth hormone secretagogue, research grade, not FDA approved
  • Sermorelin , Growth hormone releasing hormone analog, research grade, not currently FDA marketed
  • Tesamorelin , Growth hormone releasing hormone analog, FDA approved
  • Thymosin Alpha-1 , Immunomodulatory peptide, not FDA approved in the US, orphan drug status

Want the evidence layer for your practice.

A daily one page regulatory brief and a plain English PubMed literature delta, in your Drive every morning. No prescribing, no dispensing, no pharmacy routing. Just the evidence and regulatory read a prescriber wants before writing the next protocol.

Book a demoRequest access
Semaglutide clinician reference: evidence review and regulatory posture | Scriptura Health | Scriptura Health